title: Ponatinib circumvents FGF2-driven resistance to imatinib in CML.
abstract: FGF2 induces imatinib resistance in CML cells via reactivation of FGFR3-RAS-MAPK signaling.
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001549:Benzamides / Q000009:adverse effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011724:Pyridazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007093:Imidazoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; D016222:Fibroblast Growth Factor 2; C545373:ponatinib; D000068877:Imatinib Mesylate